For decades, the script of cancer immunology seemed straightforward. Tumors evade destruction by hijacking immune checkpoints—inhibitory receptors on T cells that normally apply the brakes to prevent autoimmunity. By blocking these brakes with checkpoint inhibitors, the immune system could be unleashed to attack malignancies. The concept delivered dramatic clinical successes and reshaped oncology. But as more patients received immunotherapy, a puzzling and often dangerous pattern emerged: the same drugs that shrank tumors also triggered severe inflammation in healthy organs, from colitis and pneumonitis to myocarditis and endocrine dysfunction. These multisystem immune-related adverse events hinted that checkpoint pathways were not merely local tumor escape switches but active participants in systemic immune homeostasis.
A review recently published in TransMed now argues that this duality demands a fundamental rethink of what immune checkpoints actually are. Rather than viewing molecules such as PD-1, CTLA-4, TIGIT, TIM-3, and LAG-3 as simple inhibitory receptors that dampen T-cell receptor signaling within the tumor microenvironment, the authors propose that these proteins function as central regulatory hubs that integrate local inflammatory cues with the broader physiological state of the organism. The evidence for this expanded role has been accumulating across disciplines. In autoimmune diseases, aberrant expression of checkpoint ligands on tissue cells correlates with disease flares. During chronic viral infections, sustained checkpoint signaling promotes T-cell exhaustion but also limits collateral tissue damage. In metabolic inflammation, adipose tissue macrophages upregulate PD-L1 in response to free fatty acids and hypoxia, linking nutrient excess to immune tolerance. Even after myocardial infarction, cardiac myocytes can express checkpoint ligands that shape the reparative inflammatory response.
What ties these observations together is the realization that checkpoint pathways are deeply embedded in the machinery that senses and responds to tissue stress. Inflammatory cytokines such as interferon-gamma and tumor necrosis factor can dramatically upregulate PD-L1 on parenchymal cells, while metabolic signals like lactate and reactive oxygen species modulate the expression of TIM-3 and LAG-3 on exhausted T cells. Far from being a cancer-specific adaptation, the checkpoint system appears to be a universal mechanism for enforcing tissue tolerance and pacing the intensity of immune responses against the risk of self-destruction. When this system is pharmacologically disinhibited, the ensuing toxicity is not a side effect in the traditional sense but a predictable consequence of dismantling a core homeostatic circuit.
The review systematically maps the molecular intersections between checkpoint receptors and inflammatory signaling networks. For CTLA-4, the authors highlight its role in regulating the priming of autoreactive T cells in lymph nodes, which explains why its blockade can lead to widespread lymphocytic infiltration of organs. For the PD-1/PD-L1 axis, they detail how tissue-derived stress signals—hypoxia-inducible factor 1-alpha, endoplasmic reticulum stress, and damage-associated molecular patterns—can directly induce PD-L1 on epithelial and endothelial cells, creating a shield that normally protects tissues during infection or injury but is co-opted by tumors. TIGIT, TIM-3, and LAG-3, often considered backup checkpoints, are shown to recognize distinct families of ligands, including nectins, galectins, and MHC class II molecules, that are presented differently on tumor cells, virally infected cells, and inflamed tissues, thereby providing a combinatorial code for context-dependent immune regulation.
Perhaps the most clinically consequential insight from this perspective is that precise immunomodulation may require uncoupling the anti-tumor efficacy of checkpoint blockade from its systemic inflammatory toxicity. The authors outline potential strategies emerging from this understanding. One approach involves targeting the tissue-specific drivers that upregulate checkpoint ligands, such as local cytokine blockade or metabolic modulators, to make normal cells less dependent on inhibitory signaling for protection. Another is the development of next-generation antibodies that preferentially block checkpoint interactions in the tumor microenvironment, for instance by exploiting the acidic and hypoxic conditions unique to tumors. Deeper characterization of the downstream signaling cascades—such as the recruitment of SHP-2 phosphatase by PD-1—could also reveal nodes that are differentially required in T cells fighting tumors versus those patrolling the heart or gut.
The conceptual shift carries weight because checkpoint inhibitors are entering use not just in advanced cancer but in adjuvant settings where patients may live for decades, making long-term immune safety a paramount concern. Moreover, trials are testing checkpoint agonists—drugs that stimulate rather than block inhibitory receptors—for autoimmune diseases, where the same biology could be harnessed to restore tolerance. Understanding how inflammatory metabolites, cytokines, and tissue-derived danger signals control checkpoint expression thus moves from academic interest to therapeutic necessity.
By framing immune checkpoints as integrators of local and systemic inflammation, the review offers a roadmap for the next chapter of immunotherapy. It suggests that the era of viewing these molecules through the narrow lens of tumor immune evasion is coming to an end. In its place is a picture of a dynamic, body-wide network that calibrates immunity against the constant threat of inflammatory self-harm, and that holds the key to therapies that can selectively break tolerance only where it has been pathologically imposed.
Subject of Research:
Not applicable
Article Title:
Unlocking new horizons in immunity: The roles and mechanisms of immune checkpoints in inflammation regulation
News Publication Date:
Not available
Web References:
https://doi.org/10.1016/j.tmed.2026.100021
References:
10.1016/j.tmed.2026.100021
Image Credits:
Lizhou Song, Yan Liao, Yue Shu, Wenwen Shao, Chenglong Zhu, Haoling Zhang, Yadong Guo, and Wangzheqi Zhang
